Compare PLBY & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | ARCT |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 163.4M |
| IPO Year | 2020 | 2019 |
| Metric | PLBY | ARCT |
|---|---|---|
| Price | $1.16 | $15.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.00 | ★ $24.11 |
| AVG Volume (30 Days) | 647.0K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,928,000.00 | $82,031,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.08 | $5.50 |
| 52 Week High | $2.75 | $24.14 |
| Indicator | PLBY | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 70.15 |
| Support Level | $1.09 | $6.47 |
| Resistance Level | $1.30 | N/A |
| Average True Range (ATR) | 0.05 | 1.60 |
| MACD | -0.00 | 0.35 |
| Stochastic Oscillator | 23.97 | 76.36 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.